First Wave BioPharma, Inc. (FWBI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 5.43 |
| Open | 5.38 |
| Bid | 5.11 x 1000 |
| Ask | 5.16 x 3200 |
| Day's Range | 5.05 - 5.38 |
| 52 Week Range | 3.01 - 348.60 |
| Volume | |
| Avg. Volume | 526,810 |
| Market Cap | 5.134M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.68 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 72.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for FWBI
Related Research
- First Wave BioPharma, Inc.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat4 days agoMorningstar
- GlobeNewswire
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis
Patient dosing expected to begin in mid-February with topline data anticipated by mid-2023BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the first patient was screened for the Phase 2 SPAN clinical trial investigating an enhanced enteric micro
- GlobeNewswire
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis
Patient screening to initiate; topline data expected by mid-2023BOCA RATON, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will initiate its planned Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for adrulipase
- GlobeNewswire
First Wave BioPharma to Present at the BIO CEO & Investor Conference
BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced James Sapirstein, Chairman, President and CEO, will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Details of the presentation are as fo
